Compare Aventis Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs BIOCON - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA BIOCON SANOFI INDIA/
BIOCON
 
P/E (TTM) x 46.3 30.5 151.8% View Chart
P/BV x 8.5 3.9 215.8% View Chart
Dividend Yield % 1.0 0.3 410.6%  

Financials

 SANOFI INDIA   BIOCON
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
BIOCON
Mar-19
SANOFI INDIA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs6,840707 967.1%   
Low Rs4,630554 836.0%   
Sales per share (Unadj.) Rs1,203.191.9 1,309.1%  
Earnings per share (Unadj.) Rs165.316.7 989.0%  
Cash flow per share (Unadj.) Rs209.924.2 868.1%  
Dividends per share (Unadj.) Rs84.001.00 8,400.0%  
Dividend yield (eoy) %1.50.2 923.6%  
Book value per share (Unadj.) Rs963.6101.6 948.1%  
Shares outstanding (eoy) m23.03600.00 3.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.86.9 69.5%   
Avg P/E ratio x34.737.7 92.0%  
P/CF ratio (eoy) x27.326.1 104.8%  
Price / Book Value ratio x6.06.2 95.9%  
Dividend payout %50.86.0 849.3%   
Avg Mkt Cap Rs m132,078378,330 34.9%   
No. of employees `0003.36.1 53.8%   
Total wages/salary Rs m4,06811,653 34.9%   
Avg. sales/employee Rs Th8,393.88,994.3 93.3%   
Avg. wages/employee Rs Th1,232.41,900.7 64.8%   
Avg. net profit/employee Rs Th1,153.01,635.3 70.5%   
INCOME DATA
Net Sales Rs m27,70855,144 50.2%  
Other income Rs m8971,444 62.1%   
Total revenues Rs m28,60556,588 50.5%   
Gross profit Rs m6,23515,883 39.3%  
Depreciation Rs m1,0274,478 22.9%   
Interest Rs m7709 1.0%   
Profit before tax Rs m6,09812,140 50.2%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2922,123 108.0%   
Profit after tax Rs m3,80610,026 38.0%  
Gross profit margin %22.528.8 78.1%  
Effective tax rate %37.617.5 214.9%   
Net profit margin %13.718.2 75.5%  
BALANCE SHEET DATA
Current assets Rs m15,92248,228 33.0%   
Current liabilities Rs m6,23530,376 20.5%   
Net working cap to sales %35.032.4 108.0%  
Current ratio x2.61.6 160.8%  
Inventory Days Days6468 93.2%  
Debtors Days Days2186 24.4%  
Net fixed assets Rs m7,53964,130 11.8%   
Share capital Rs m2303,000 7.7%   
"Free" reserves Rs m21,96257,980 37.9%   
Net worth Rs m22,19260,980 36.4%   
Long term debt Rs m015,766 0.0%   
Total assets Rs m29,839121,924 24.5%  
Interest coverage x872.118.1 4,812.4%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.5 205.3%   
Return on assets %12.88.8 145.1%  
Return on equity %17.216.4 104.3%  
Return on capital %27.516.8 164.2%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m7,58715,506 48.9%   
Fx outflow Rs m7,14510,399 68.7%   
Net fx Rs m4425,107 8.7%   
CASH FLOW
From Operations Rs m3,73911,546 32.4%  
From Investments Rs m-731-7,138 10.2%  
From Financial Activity Rs m-1,972-2,417 81.6%  
Net Cashflow Rs m1,0362,103 49.3%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 60.4 20.6 293.2%  
Indian inst/Mut Fund % 14.4 8.4 171.4%  
FIIs % 14.6 10.7 136.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   15,184 109,995 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  ELDER PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

Elon Musk Gives Us a Trading Opportunity(Fast Profits Daily)

Jul 28, 2020

Elon Musk made a statement recently which I believe, gives us a fast profit trading opportunity.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 7, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - DR. DATSONS LABS COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS